ストックスクリーナーアプリを入手
67.82
2.27%
-1.571
前日終値:
$69.39
開ける：
$69.24
24時間の取引高:
471.55K
Relative Volume:
0.71
時価総額：
$3.74B
収益：
$76.81M
当期純損益:
$-162.42M
株価収益率:
-22.68
EPS:
-2.99
ネットキャッシュフロー:
$-122.49M
1週間 パフォーマンス:
-0.48%
1か月 パフォーマンス:
+7.65%
6か月 パフォーマンス:
+2.99%
1年 パフォーマンス:
+7.70%
1日の値動き範囲:
$66.52
$69.24
1週間の範囲:
$66.52
$71.58
52週間の値動き範囲:
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
ACLX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
67.84 | 3.85B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.46 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.48 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.11 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.95 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.63 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-09-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-03-07 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-04 | 繰り返されました | Needham | Buy |
| 2023-12-19 | 開始されました | Scotiabank | Sector Outperform |
| 2023-10-30 | 開始されました | TD Cowen | Outperform |
| 2023-10-17 | 開始されました | UBS | Buy |
| 2023-05-18 | 開始されました | Truist | Buy |
| 2023-04-14 | 開始されました | Robert W. Baird | Outperform |
| 2023-03-14 | 開始されました | Stifel | Buy |
| 2023-02-13 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-13 | 再開されました | BofA Securities | Buy |
| 2022-10-31 | 開始されました | Guggenheim | Buy |
| 2022-10-27 | 開始されました | Needham | Buy |
| 2022-07-20 | 開始されました | Canaccord Genuity | Buy |
| 2022-03-01 | 開始されました | BofA Securities | Buy |
| 2022-03-01 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Arcellx Inc (ACLX) 最新ニュース
Is Arcellx Inc. a good long term investmentFree Trading Strategy Suggestions - jammulinksnews.com
What drives Arcellx Inc. stock priceUnrivaled growth potential - jammulinksnews.com
Bank of New York Mellon Corp Cuts Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
What analysts say about Arcellx Inc. stockExceptional risk-adjusted gains - jammulinksnews.com
Principal Financial Group Inc. Sells 184 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Xponance Inc. Acquires 190 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
There's Reason For Concern Over Arcellx, Inc.'s (NASDAQ:ACLX) Price - 富途牛牛
Arcellx Advances Phase 3 Study for Multiple Myeloma Treatment - TipRanks
Teacher Retirement System of Texas Decreases Stake in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx; Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market (ACLX) - Seeking Alpha
What makes Arcellx Inc. stock price move sharplyElite Stock Shortlist - Newser
Why Arcellx Inc. stock attracts strong analyst attentionFree High-Accuracy Stock Picks - Newser
GAMMA Investing LLC Buys 252 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Amalgamated Bank Buys 161 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Allspring Global Investments Holdings LLC Has $468,000 Stock Position in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
How might ACLX's 2025 Q1 EPS forecast affect strategies? - AInvest
Piper Sandler maintains Overweight rating on Arcellx stock amid CAR-T safety study - Investing.com Nigeria
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers - Benzinga
(ACLX) Trading Signals - news.stocktradersdaily.com
Citi initiates Arcellx stock with buy rating on cell therapy potential - Investing.com
Citi initiates Arcellx stock with buy rating on cell therapy potential By Investing.com - Investing.com South Africa
Cancer Cell Market Exclusive Report with Detailed Study Analysis | Abbott Laboratories, Cellectis, Arcellx, GE - newstrail.com
Citigroup Initiates Arcellx at Buy With $110 Price Target - MarketScreener
Arcellx initiated with a Buy at Citi - TipRanks
Arcellx (ACLX): Citi Initiates Buy Rating with Promising Outlook | ACLX Stock News - GuruFocus
Aileen Fernandes | People on The MoveSan Francisco Business Times - The Business Journals
Aileen Fernandes - The Business Journals
Arcellx Inc’s Anito-cel: A Promising Market Entrant with Superior Efficacy and Safety in Multiple Myeloma Treatment - TipRanks
Arcellx Inc’s Anito Cel Therapy: A Promising Contender in Multiple Myeloma Treatment with Strong Market Potential - TipRanks
ACLX: HC Wainwright & Co. Reiterates Buy Rating with $115 Target | ACLX Stock News - GuruFocus
Arcellx stock maintains buy rating at H.C. Wainwright on launch plans - Investing.com
Arcellx Inc’s Strategic Partnership with Kite Enhances Anito-cel Therapy Launch and Market Position - TipRanks
Promising Potential of Arcellx Inc’s Anito-cel Therapy Drives Buy Rating - TipRanks
Positive Outlook for Arcellx Inc: Promising Anito-cel Therapy and Strategic Market Positioning - TipRanks
Arcellx Inc’s Promising Market Position and Growth Potential in Multiple Myeloma Therapy - TipRanks
Rhumbline Advisers Raises Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx Inc (ACLX) 財務データ
収益
当期純利益
現金流量
EPS
0.55%
大文字化:
|
ボリューム (24 時間):